Claims for Patent: 7,160,983

Summary for Patent: 7,160,983

Title:	Echinocandin derivatives, their method of preparation and their application as anti-fungal agents
Abstract:	Compound of the formula ##STR00001## wherein R.sub.2 is --CH.sub.2--CH.sub.2--NH.sub.2, R.sub.3 is --CH.sub.3, R.sub.4 is --OH, R is ##STR00002## Z is methyl and salts thereof which are useful as antifungal agents.
Inventor(s):	Courtin; Olivier (Paris, FR), Fauveau; Patrick (Livry Gargan, FR), Markus; Astrid (Liederbach, DE), Melon Manguer; Dominique (Montreuil, FR), Michel; Jean-Marc (Compiegne, FR), Schio; Laurent (Bondy, FR)
Assignee:	Aventis Pharma S.A. (FR)
Application Number:	10/666,072
Patent Claims:	1. A compound of the formula: ##STR00019## wherein R is ##STR00020## or a pharmaceutically acceptable acid addition salt thereof. 2. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable carrier. 3. The method of claim 2 in which said pharmaceutically acceptable carrier comprises apyrogenic sterile water. 4. The pharmaceutical composition of claim 2 which is in the form of a sugar coated tablet, capsule, granule, suppository, injectable preparation, ointment, cream or gel. 5. A method of treating an ailment caused by exposure to a fungus comprising administering to a person in need thereof a pharmaceutical composition according to claim 2. 6. A method of treating an ailment in a person caused by exposure to a fungus comprising administering to a person in need thereof an antifungally effective amount of a compound of claim 1. 7. The method of claim 6 in which said fungus is selected from the group consisting of Candida albicans, Candida glabrate, Candida krusei, Candida tropicalis, Candida pseudotropicalis, porapsilosis, Aspergillus fumigatus, Aspergillus flavus, and Cryptococcus neoformans. 8. The method of claim 6 in which said ailment is selected from the group consisting of digestive, urinary, vaginal or cutaneous candidoses, cryptococcoses, neuromenengeal, pulmonary or cutaneous cryptococcoses, bronchopulmonary and pulmonary aspergilloses and invasive aspergilloses in an immunocompromised subject. 9. The method of claim 6 which is directed to the treatment of mycosic ailments in people with congenital or acquired immune compromise. 10. The method of claim 6 in which the effective amount ranges from about 50 mg to about 300 mg per day. 11. A method of treating an ailment caused by exposure to a fungus comprising administering to a person in need thereof an antifungally effective amount of a compound of claim 1.

Details for Patent 7,160,983

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2017-12-10